coronavirus

Medicare to cover all FDA-approved Covid-19 vaccines

  • by

CMS’ interim rule states that Medicare will cover Covid-19 vaccines approved by the FDA, including those receiving emergency use authorization, in a reversal from its usual policy. The vaccine will be made available at no cost to Medicare beneficiaries.

Technology can ease pandemic challenges faced by hospitals, ambulatory surgery centers

  • by

To keep critical revenue flowing, hospitals and ambulatory surgery centers need to resume elective surgeries and procedures as quickly as possible and mobile apps can help by giving patients and staff vital information, provide advance symptom screening and help providers reduce elective procedure no-shows through… Read More »Technology can ease pandemic challenges faced by hospitals, ambulatory surgery centers

BCG – COVID-19 Hackathon Challenge Now Extended Through End of Year

  • by

A renewed interest in whether the BCG vaccine (for tuberculosis) could also have an application for COVID-19 has been on the rise, as evidenced by this recent Cell publication, the University of Exeter’s involvement in the BRACE Trial and ongoing general press coverage. Furthermore, the list of clinical trials focusing… Read More »BCG – COVID-19 Hackathon Challenge Now Extended Through End of Year

Analysis: COVID-19 Ranks as a Top 3 Leading Cause of Death in the U.S., Higher than in Almost All Other Peer Countries

  • by

A new KFF analysis examines leading causes of death and mortality rates in the United States and comparable countries. The U.S. has a higher COVID-19 mortality rate than many of its peer countries, with COVID-19 ranking as the nation’s third-leading cause of death in 2020,… Read More »Analysis: COVID-19 Ranks as a Top 3 Leading Cause of Death in the U.S., Higher than in Almost All Other Peer Countries

This Week in Coronavirus: October 9 to October 15

  • by

Total confirmed cases in the U.S. surpassed 7.9 million this week. There was an approximate increase of 373,800 confirmed cases between October 9 and October 15. Approximately 4,900 confirmed deaths in the past week brought the total in the United States to approximately 217,700.  

Boots bosses ‘encouraged’ staff to work at head office despite UK government advice

  • by

Emails show senior managers ‘expecting’ attendance at Nottingham HQ despite big spike in local cases Coronavirus – latest updates See all our coronavirus coverage Boots told staff they were “encouraged” to come in to its headquarters in Nottingham, where Covid-19 infection rates are the highest… Read More »Boots bosses ‘encouraged’ staff to work at head office despite UK government advice

Cue Health gets $481M to expand production of rapid coronavirus test

  • by

San Diego-based diagnostics startup Cue Health won a $481 million from the Department of Health and Human Services and the Department of Defense to produce more coronavirus tests. The company received an emergency use authorization in June for its rapid molecular test.

CMS promises a plan for Medicare to cover coronavirus vaccine

  • by

Medicare doesn’t currently cover drugs approved under emergency use designations. But  CMS Administrator Seema Verma said the agency was coming up with a plan to make sure Medicare beneficiaries were covered once a coronavirus vaccine is developed.

Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments

  • by

In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today, we’re diving deeper into CMS’s proposal to vastly expand the types of medicines that would fall… Read More »Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments

Johnson & Johnson pauses Covid vaccine trial over participant’s ‘unexplained illness’

  • by

Company is unclear about whether patient was receiving vaccine or placebo in 60,000-patient study Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed. The pharmaceutical giant was unclear if the patient was administered a… Read More »Johnson & Johnson pauses Covid vaccine trial over participant’s ‘unexplained illness’

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

  • by

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients… Read More »The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rival

  • by

GlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting heat on Regeneron’s rival that has been famously used to treat president Donald Trump. GSK and Vir began trials of the antibody on early-stage COVID-19 patients in… Read More »GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rival

How the value of innovation will be redefined in 2021

  • by

While payers and policymakers took a more narrow-minded perspective on innovation value in 2020, the year 2021 will bring an increased focus on a treatment’s societal value, how innovation interacts with digital technologies, and whether new innovations are able to reduce existing health outcome inequalities.

Why the U.S. biopharmaceutical industry is leading the charge against COVID-19

  • by

The rapid spread and impact of COVID-19 has sparked a global race to find effective treatments and preventative vaccines with the U.S. biopharmaceutical industry leading the charge. America’s biopharmaceutical companies are working together in unprecedented collaboration, to defeat COVID-19 by developing the innovative tests, treatments,… Read More »Why the U.S. biopharmaceutical industry is leading the charge against COVID-19

Timing of Remdesivir for COVID-19

  • by

Date:  October 19, 2020 Issue #:  1609 Summary:  Remdesivir (Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use of the… Read More »Timing of Remdesivir for COVID-19

Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19

  • by

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we… Read More »Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19

BCG-COVID 19 Hackathon: Task 1 winners announced, Task 2 – data scientists – we need you!

  • by

We’ve seen the scientific community come together time and again throughout the COVID-19 pandemic, and we’re thrilled to have been part of a hackathon bringing together data scientists, epidemiologists and partner organizations focusing on analysing the hypothesis of whether the tuberculosis (TB) vaccine – BCG… Read More »BCG-COVID 19 Hackathon: Task 1 winners announced, Task 2 – data scientists – we need you!

Modeling Coronavirus – Cytokine Storm

  • by

Figure 1. Classification of COVID-19 Disease States.Adapted from Sidiqi, H.K. and M.R. Mehra, COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant, 2020. [1] (This piece was co-authored by Prof. Gordon Broderick, Clinical Systems Biology at Rochester General Hospital.) The thing… Read More »Modeling Coronavirus – Cytokine Storm

FDA’s emergency authorization for convalescent plasma in Covid-19 sparks controversy

  • by

While the emergency use authorization granted Sunday was not seen as scientifically unwarranted, it drew concerns from some experts that it could hinder enrollment in clinical trials, while the timing and circumstances of the FDA’s move fueled suspicions that political pressure – rather than science… Read More »FDA’s emergency authorization for convalescent plasma in Covid-19 sparks controversy

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

  • by

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients… Read More »The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

What would post-Covid value-based care look like?

  • by

As virtual care is only going to grow in the coming months as a solution to pent-up demand for care that has resulted from the pandemic, focused attention is needed to address these operational and reimbursement issues.

[Podcast] How Cleveland Clinic Helps Employers Create a Safer Workplace During COVID-19

  • by

Dr. Jim Merlino, Chief Clinical Transformation Officer, Cleveland Clinic Despite having entered the US eight months ago, COVID-19 remains a topic enshrouded in confusion, conflicting information, hyperbole, and even conspiracy theories. Everyone, informed or not, seems to have an opinion about the coronavirus pandemic. Fortunately,… Read More »[Podcast] How Cleveland Clinic Helps Employers Create a Safer Workplace During COVID-19

How wearables can help the healthcare industry address Covid-19

  • by

The potential that wearables have for helping detect early signs of Covid-19 and other infectious diseases, as well as monitoring patients, will make this technology a popular choice for healthcare organizations and consumers for the foreseeable future.

Trust, privacy, and our American pandemic 

  • by

Health information exchanges know about the hard work of building trust by delivering value in healthcare. They have been in these trenches. They need a seat at the table with our state public health leaders as America works to safely reopen.

Trump reiterates hydroxychloroquine defense after son is banned from Twitter

  • by

Donald Trump has launched another defence of hydroxychloroquine as a treatment for COVID-19 which goes against prevailing medical advice. The President’s comments came after Twitter banned his eldest son from tweeting for 12 hours, after he posted a video which repeated the assertion that hydroxychloroquine… Read More »Trump reiterates hydroxychloroquine defense after son is banned from Twitter

Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out

  • by

Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after a 23 million euro ($27 million) financing round. ExeVir is a spin-out of Vlaams Instituut voor Biotechnologie (VIB), Belgium’s life sciences research institute and the company also… Read More »Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out

Pfizer, BioNTech start late-stage study of Covid-19 vaccine

  • by

The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III study and days after Pfizer and BioNTech signed a nearly $2 billion vaccine supply deal with the federal government.

Trump’s tweets advocate hydroxychloroquine as big COVID-19 vaccine trials start

  • by

Hydroxychloroquine, the anti-malaria drug controversially used to fight COVID-19, was trending again after a string of retweets from president Donald Trump in favour of the medicine. Trump has championed hydroxychloroquine, which was first touted as a potential cure for COVID-19 by the French doctor Didier… Read More »Trump’s tweets advocate hydroxychloroquine as big COVID-19 vaccine trials start

The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

  • by

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients… Read More »The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19

  • by

Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing COVID-19 pandemic gripping the world, we are experiencing a challenging situation that we haven’t seen… Read More »New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19

Synairgen’s inhaled drug cuts chances of COVID-19 progressing

  • by

An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease.  Southampton-based Synairgen said in a preliminary trial readout that the company’s SNG001 – an inhaled formulation of interferon beta – reduced risk of progression… Read More »Synairgen’s inhaled drug cuts chances of COVID-19 progressing